Menu
NASP

All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information

Featured Activity

Learn about treatment options, treatment failure, associated adverse effects and more.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

SHOW SEARCH

State of Care: Oncology/Hematology

To Participate

To participate in this continuing education activity:

  1. Review the activity description and objectives.
  2. View the activity.
  3. Complete the online post-test and activity evaluation.

NOTE: If you attended this live CE activity that was held during the 2019 NASP Annual Meeting & Expo in Washington, DC AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-9999-19-463-L01-P), you are ineligible to also receive CE credit for this home-study activity.

This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.


 

A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities
 

Activity Description

This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). This activity was originally presented during the 2019 National Association of Specialty Pharmacy Annual Meeting & Expo held in Washington, DC. This activity will focus on acute myeloid leukemia and multiple myeloma with a review of the current standards of care for this disease state. Ways to help patients manage the disease and a review of the newest agents for this disease state will also be included.

Learning Objectives

The target audience for this activity is pharmacists. Upon completion of this activity, participants will be able to:

  • Identify new agents that have been approved over the last 12 months.
  • Examine current standards of care within this disease area with focus on acute myeloid leukemia and multiple myeloma.
  • Examine clinical pearls and best practices for clinically managing patients within disease process.

Faculty

Joseph Barone, PharmD, BCOP
Director of Clinical Oncology Services
Onco360 Oncology Pharmacy

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Joseph Barone has no relevant financial and/or commercial relationships to disclose.

CE Accreditation

Release Date: 5-29-2020
Expiration Date: 5-29-2023

Pharmacists

This CE activity is jointly provided by ProCE, Inc. and NASP. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-258-H01-P has been assigned to this knowledge-based home-study CE activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given.

Funding

No external support has been received for this activity.

 

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.